Global Tagrisso (Osimertinib) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Tagrisso (Osimertinib) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Tagrisso, also known by its generic name Osimertinib, is a medication used to treat certain types of non-small cell lung cancer (NSCLC). It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), which work by blocking the action of certain proteins involved in the growth and spread of cancer cells. Tagrisso is specifically used for the treatment of NSCLC that has certain mutations in the epidermal growth factor receptor (EGFR) gene.
Tagrisso (Osimertinib) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Tagrisso (Osimertinib) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Locally Advanced NSCLC and Metastatic NSCLC are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Tagrisso (Osimertinib) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Tagrisso (Osimertinib) key manufacturers include AstraZeneca, Incepta Pharmaceuticals Ltd, Lonza AG, Everest Pharmaceuticals, Beacon Pharmaceuticals Limited and Drug International Limited, etc. AstraZeneca, Incepta Pharmaceuticals Ltd, Lonza AG are top 3 players and held % sales share in total in 2022.
Tagrisso (Osimertinib) can be divided into 40 mg and 80 mg, etc. 40 mg is the mainstream product in the market, accounting for % sales share globally in 2022.
Tagrisso (Osimertinib) is widely used in various fields, such as Locally Advanced NSCLC, Metastatic NSCLC and Other,, etc. Locally Advanced NSCLC provides greatest supports to the Tagrisso (Osimertinib) industry development. In 2022, global % sales of Tagrisso (Osimertinib) went into Locally Advanced NSCLC filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tagrisso (Osimertinib) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
AstraZeneca
Incepta Pharmaceuticals Ltd
Lonza AG
Everest Pharmaceuticals
Beacon Pharmaceuticals Limited
Drug International Limited
Segment by Type
40 mg
80 mg
Locally Advanced NSCLC
Metastatic NSCLC
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Tagrisso (Osimertinib) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Tagrisso (Osimertinib), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Tagrisso (Osimertinib) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Tagrisso (Osimertinib) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Tagrisso (Osimertinib) introduction, etc. Tagrisso (Osimertinib) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Tagrisso (Osimertinib) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Tagrisso (Osimertinib) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Tagrisso (Osimertinib) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Locally Advanced NSCLC and Metastatic NSCLC are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Tagrisso (Osimertinib) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Tagrisso (Osimertinib) key manufacturers include AstraZeneca, Incepta Pharmaceuticals Ltd, Lonza AG, Everest Pharmaceuticals, Beacon Pharmaceuticals Limited and Drug International Limited, etc. AstraZeneca, Incepta Pharmaceuticals Ltd, Lonza AG are top 3 players and held % sales share in total in 2022.
Tagrisso (Osimertinib) can be divided into 40 mg and 80 mg, etc. 40 mg is the mainstream product in the market, accounting for % sales share globally in 2022.
Tagrisso (Osimertinib) is widely used in various fields, such as Locally Advanced NSCLC, Metastatic NSCLC and Other,, etc. Locally Advanced NSCLC provides greatest supports to the Tagrisso (Osimertinib) industry development. In 2022, global % sales of Tagrisso (Osimertinib) went into Locally Advanced NSCLC filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tagrisso (Osimertinib) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AstraZeneca
Incepta Pharmaceuticals Ltd
Lonza AG
Everest Pharmaceuticals
Beacon Pharmaceuticals Limited
Drug International Limited
Segment by Type
40 mg
80 mg
Segment by Application
Locally Advanced NSCLC
Metastatic NSCLC
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Tagrisso (Osimertinib) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Tagrisso (Osimertinib), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Tagrisso (Osimertinib) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Tagrisso (Osimertinib) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Tagrisso (Osimertinib) introduction, etc. Tagrisso (Osimertinib) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Tagrisso (Osimertinib) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices